PriceTargets.com logo

Zimmer Biomet - ZBH Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $123.33
  • Forecasted Upside: 15.14%
  • Number of Analysts: 20
  • Breakdown:
  • 2 Sell Ratings
  • 11 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$107.12 As of 12/20/2024 06:31 PM ET
▲ +1.31 (1.24%)

This chart shows the closing price for ZBH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Zimmer Biomet Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ZBH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ZBH

Analyst Price Target is $123.33
▲ +15.14% Upside Potential
This price target is based on 20 analysts offering 12 month price targets for Zimmer Biomet in the last 3 months. The average price target is $123.33, with a high forecast of $150.00 and a low forecast of $107.00. The average price target represents a 15.14% upside from the last price of $107.12.

This chart shows the closing price for ZBH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 20 polled investment analysts is to hold stock in Zimmer Biomet. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 7 hold ratings
  • 2 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 7 hold ratings
  • 2 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 8 hold ratings
  • 2 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 9 hold ratings
  • 2 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 9 hold ratings
  • 1 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 12 hold ratings
  • 2 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 12 hold ratings
  • 2 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 11 hold ratings
  • 2 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 11 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/18/2024Truist FinancialBoost TargetHold ➝ Hold$117.00 ➝ $118.00
12/17/2024JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$125.00 ➝ $128.00
12/12/2024BarclaysLower TargetUnderweight ➝ Underweight$125.00 ➝ $118.00
11/4/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$120.00 ➝ $125.00
11/1/2024Truist FinancialBoost TargetHold ➝ Hold$112.00 ➝ $117.00
10/31/2024Wells Fargo & CompanyBoost TargetEqual Weight ➝ Equal Weight$110.00 ➝ $117.00
10/31/2024Needham & Company LLCReiterated RatingHold
10/15/2024OppenheimerLower TargetOutperform ➝ Outperform$145.00 ➝ $135.00
10/14/2024Raymond JamesLower TargetOutperform ➝ Outperform$128.00 ➝ $123.00
10/8/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$130.00 ➝ $120.00
10/3/2024BTIG ResearchLower TargetBuy ➝ Buy$134.00 ➝ $126.00
10/1/2024Evercore ISILower TargetIn-Line ➝ In-Line$113.00 ➝ $110.00
9/17/2024Needham & Company LLCReiterated RatingHold
9/16/2024JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$125.00 ➝ $120.00
9/13/2024Truist FinancialReiterated RatingHold ➝ Hold$117.00 ➝ $112.00
9/10/2024Canaccord Genuity GroupLower TargetHold ➝ Hold$120.00 ➝ $115.00
9/10/2024Wolfe ResearchInitiated CoveragePeer Perform
9/6/2024TD CowenLower TargetHold ➝ Hold$143.00 ➝ $119.00
9/5/2024Evercore ISIReiterated RatingIn-Line ➝ In-Line$113.00 ➝ $113.00
9/5/2024Truist FinancialReiterated RatingHold ➝ Hold$117.00 ➝ $117.00
8/20/2024Canaccord Genuity GroupLower TargetHold ➝ Hold$130.00 ➝ $120.00
8/8/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$140.00 ➝ $130.00
8/8/2024Raymond JamesLower TargetOutperform ➝ Outperform$138.00 ➝ $128.00
8/8/2024UBS GroupLower TargetSell ➝ Sell$112.00 ➝ $107.00
8/8/2024Evercore ISILower TargetIn-Line ➝ In-Line$115.00 ➝ $113.00
8/8/2024Needham & Company LLCReiterated RatingHold
8/8/2024Robert W. BairdLower TargetOutperform ➝ Outperform$155.00 ➝ $145.00
8/8/2024OppenheimerLower TargetOutperform ➝ Outperform$155.00 ➝ $145.00
7/16/2024Truist FinancialLower TargetHold ➝ Hold$130.00 ➝ $117.00
7/15/2024Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$130.00 ➝ $120.00
7/10/2024CitigroupLower TargetNeutral ➝ Neutral$134.00 ➝ $120.00
7/2/2024Evercore ISILower TargetIn-Line ➝ In-Line$130.00 ➝ $115.00
7/1/2024Piper SandlerDowngradeOverweight ➝ Neutral$140.00 ➝ $115.00
5/31/2024BarclaysLower TargetUnderweight ➝ Underweight$130.00 ➝ $125.00
5/30/2024Needham & Company LLCReiterated RatingHold
5/30/2024The Goldman Sachs GroupInitiated CoverageNeutral$129.00
5/21/2024ArgusUpgradeHold ➝ Buy$150.00
5/17/2024Needham & Company LLCReiterated RatingHold
5/3/2024Truist FinancialLower TargetHold ➝ Hold$137.00 ➝ $130.00
5/3/2024OppenheimerBoost TargetOutperform ➝ Outperform$150.00 ➝ $155.00
5/2/2024Needham & Company LLCReiterated RatingHold
4/4/2024Evercore ISIBoost TargetIn-Line ➝ In-Line$125.00 ➝ $130.00
4/3/2024CitigroupBoost TargetNeutral ➝ Neutral$134.00 ➝ $140.00
2/23/2024Canaccord Genuity GroupReiterated RatingHold ➝ Hold$130.00
2/12/2024BarclaysBoost TargetUnderweight ➝ Underweight$120.00 ➝ $130.00
2/9/2024Truist FinancialBoost TargetHold ➝ Hold$133.00 ➝ $135.00
2/9/2024JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$115.00 ➝ $125.00
2/9/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$140.00
1/12/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$134.00 ➝ $140.00
1/4/2024Evercore ISIDowngradeOutperform ➝ Inline$135.00 ➝ $125.00
1/3/2024Raymond JamesBoost TargetOutperform ➝ Outperform$133.00 ➝ $137.00
12/22/2023Truist FinancialBoost TargetHold ➝ Hold$115.00 ➝ $133.00
12/4/2023Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$120.00 ➝ $125.00
11/13/2023JMP SecuritiesLower TargetMarket Outperform ➝ Market Outperform$160.00 ➝ $140.00
11/9/2023Raymond JamesLower TargetOutperform ➝ Outperform$160.00 ➝ $133.00
11/8/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$140.00 ➝ $120.00
11/8/2023JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$146.00 ➝ $115.00
10/20/2023Roth MkmInitiated CoverageNeutral$120.00
10/2/2023CitigroupLower TargetNeutral ➝ Neutral$146.00 ➝ $125.00
8/28/2023BTIG ResearchUpgradeNeutral ➝ Buy$139.00
8/2/2023OppenheimerReiterated RatingOutperform ➝ Outperform$157.00
8/2/2023JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$160.00
8/2/2023Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$140.00
8/2/2023Truist FinancialLower TargetHold ➝ Hold$153.00 ➝ $148.00
8/2/2023UBS GroupBoost Target$116.00 ➝ $125.00
8/2/2023BarclaysBoost TargetUnderweight ➝ Underweight$116.00 ➝ $120.00
7/19/2023Truist FinancialBoost Target$147.00 ➝ $153.00
5/18/202322nd Century GroupReiterated RatingMaintains
5/18/2023888Reiterated RatingMaintains
5/18/2023Stifel NicolausBoost Target$160.00 ➝ $165.00
5/18/2023Truist FinancialLower Target$153.00 ➝ $147.00
5/4/2023BarclaysBoost Target$105.00 ➝ $116.00
5/3/202358.comReiterated RatingMaintains
5/3/2023Deutsche Bank AktiengesellschaftBoost Target$121.00 ➝ $147.00
5/3/2023Truist FinancialBoost Target$137.00 ➝ $153.00
5/3/2023FIG PartnersUpgradeNeutral
5/3/2023Bank of AmericaUpgradeUnderperform ➝ Neutral
5/3/2023Royal Bank of CanadaBoost Target$141.00 ➝ $156.00
5/3/2023Raymond JamesBoost Target$144.00 ➝ $160.00
5/3/2023Robert W. BairdBoost Target$145.00 ➝ $172.00
5/3/2023JMP SecuritiesBoost Target$145.00 ➝ $160.00
5/3/2023Sanford C. BernsteinBoost Target$136.00 ➝ $152.00
4/11/2023Evercore ISIUpgradeIn-Line ➝ Outperform$135.00 ➝ $148.00
3/31/2023Jefferies Financial GroupUpgradeUnderperform ➝ Hold$115.00 ➝ $130.00
3/28/2023UBS GroupInitiated CoverageSell$112.00
3/9/2023Piper SandlerUpgradeNeutral ➝ Overweight$135.00 ➝ $145.00
2/7/2023JMP SecuritiesReiterated RatingMarket Outperform$145.00
2/6/2023Loop CapitalBoost Target$125.00 ➝ $140.00
2/6/2023OppenheimerBoost TargetOutperform$120.00 ➝ $142.00
2/6/2023Morgan StanleyBoost TargetEqual Weight$135.00 ➝ $140.00
2/6/2023Truist FinancialBoost TargetHold$135.00 ➝ $137.00
2/6/2023Robert W. BairdBoost Target$133.00 ➝ $145.00
2/3/2023Piper SandlerBoost Target$130.00 ➝ $135.00
1/9/2023Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$125.00 ➝ $141.00
1/6/2023Morgan StanleyBoost TargetEqual Weight$120.00 ➝ $135.00
1/5/2023Piper SandlerBoost Target$120.00 ➝ $130.00
1/5/2023Raymond JamesUpgradeMarket Perform ➝ Outperform$144.00
1/3/2023Evercore ISIDowngradeOutperform ➝ Inline$130.00
12/20/2022Truist FinancialBoost TargetHold$120.00 ➝ $135.00
12/12/2022CitigroupBoost TargetNeutral$116.00 ➝ $130.00
11/23/2022Wells Fargo & CompanyUpgradeUnderweight ➝ Equal Weight$116.00 ➝ $124.00
11/3/2022Royal Bank of CanadaLower TargetSector Perform$128.00 ➝ $125.00
11/3/2022CitigroupLower TargetNeutral$119.00 ➝ $116.00
10/17/2022BarclaysInitiated CoverageUnderweight$104.00
10/12/2022Jefferies Financial GroupInitiated CoverageUnderperform$95.00
8/3/2022Morgan StanleyBoost TargetEqual Weight$115.00 ➝ $120.00
8/3/2022CitigroupBoost Target$114.00 ➝ $119.00
8/2/2022Piper SandlerLower Target$130.00 ➝ $120.00
7/22/2022Truist FinancialLower Target$115.00
7/18/2022Stifel NicolausLower Target$140.00 ➝ $120.00
7/15/2022Morgan StanleyLower TargetEqual Weight$132.00 ➝ $115.00
5/27/2022Needham & Company LLCDowngradeBuy ➝ Hold
5/17/2022CitigroupLower TargetNA$135.00 ➝ $125.00
5/4/2022Truist FinancialLower Target$142.00 ➝ $131.00
5/3/2022Stifel NicolausBoost Target$130.00 ➝ $140.00
4/13/2022Truist FinancialDowngradeBuy ➝ Hold$128.00 ➝ $142.00
4/1/2022CitigroupDowngradeBuy ➝ Neutral$125.15 ➝ $135.00
3/21/2022The Goldman Sachs GroupLower TargetBuy$179.00 ➝ $155.00
3/2/2022Loop CapitalDowngradeBuy ➝ Hold$130.00
3/1/2022Bank of AmericaInitiated CoverageUnderperform ➝ Underperform$120.00
2/9/2022Loop CapitalLower TargetBuy$165.00 ➝ $140.00
2/8/2022CitigroupLower TargetBuy$150.00 ➝ $129.00
2/8/2022Stifel NicolausLower TargetBuy$178.00 ➝ $130.00
2/8/2022JPMorgan Chase & Co.Lower TargetNeutral$150.00 ➝ $114.00
2/8/2022Royal Bank of CanadaLower TargetSector Perform$140.00 ➝ $125.00
2/8/2022Truist FinancialLower TargetBuy$145.00 ➝ $128.00
2/8/2022Deutsche Bank AktiengesellschaftLower TargetHold$140.00 ➝ $121.00
2/8/2022Wells Fargo & CompanyLower TargetUnderweight$124.00 ➝ $111.00
2/8/2022JMP SecuritiesLower TargetOutperform$175.00 ➝ $145.00
2/8/2022Canaccord Genuity GroupDowngradeBuy ➝ Hold$165.00 ➝ $125.00
2/8/2022Needham & Company LLCLower TargetBuy$155.00 ➝ $143.00
2/8/2022Leerink PartnersLower TargetOutperform$150.00 ➝ $135.00
2/7/2022Piper SandlerLower Target$135.00 ➝ $110.00
2/2/2022UBS GroupDowngradeBuy ➝ Neutral$172.00 ➝ $130.00
1/21/2022Needham & Company LLCLower TargetBuy$158.00 ➝ $155.00
1/19/2022Wells Fargo & CompanyDowngradeEqual Weight ➝ Underweight$170.00 ➝ $124.00
1/10/2022MizuhoDowngradeBuy ➝ Neutral
1/10/2022BTIG ResearchDowngradeBuy ➝ Neutral
1/7/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight$165.00 ➝ $145.00
1/4/2022Piper SandlerDowngradeOverweight ➝ Neutral$185.00 ➝ $135.00
12/21/2021Truist FinancialLower TargetBuy$175.00 ➝ $145.00
12/9/2021Royal Bank of CanadaInitiated CoverageSector Perform$140.00
12/9/2021Needham & Company LLCDowngradeStrong-Buy ➝ Buy$175.00 ➝ $158.00
12/6/2021Loop CapitalInitiated CoverageBuy$165.00
11/23/2021ArgusDowngradeBuy ➝ Hold
11/5/2021JMP SecuritiesLower TargetMarket Outperform$195.00 ➝ $175.00
11/5/2021Jefferies Financial GroupLower TargetBuy$200.00 ➝ $175.00
11/5/2021CitigroupLower TargetBuy$188.00 ➝ $175.00
11/5/2021Deutsche Bank AktiengesellschaftLower TargetHold$160.00 ➝ $140.00
11/5/2021BTIG ResearchLower TargetPositive ➝ Buy$173.00 ➝ $161.00
11/4/2021Piper SandlerLower TargetOverweight$195.00 ➝ $185.00
10/22/2021Leerink PartnersReiterated RatingOutperform
10/5/2021BarclaysLower TargetOverweight$210.00 ➝ $186.00
10/1/2021CitigroupLower TargetBuy$200.00 ➝ $188.00
9/14/2021Robert W. BairdReiterated RatingBuy
9/14/2021Raymond JamesInitiated CoverageMarket Perform
8/4/2021Leerink PartnersLower TargetOutperform$205.00 ➝ $196.00
8/4/2021OppenheimerLower TargetOutperform$195.00 ➝ $190.00
8/3/2021Stifel NicolausLower TargetPositive ➝ Buy$190.00 ➝ $185.00
5/25/2021BarclaysInitiated CoverageOverweight$210.00
5/17/2021JMP SecuritiesBoost TargetMarket Outperform$180.00 ➝ $195.00
5/11/2021JMP SecuritiesBoost TargetOutperform$180.00 ➝ $195.00
5/5/2021Truist FinancialBoost Target$174.00 ➝ $188.00
5/5/2021Raymond JamesBoost TargetStrong-Buy$187.00 ➝ $200.00
5/5/2021Leerink PartnersBoost TargetOutperform$200.00 ➝ $205.00
5/5/2021OppenheimerBoost TargetOutperform$185.00 ➝ $195.00
4/15/2021Northland SecuritiesUpgradeMarket Perform ➝ Outperform$165.00 ➝ $200.00
4/9/2021Northland SecuritiesUpgradeMarket Perform ➝ Outperform
3/8/2021OppenheimerBoost TargetOutperform$173.00 ➝ $185.00
3/1/2021Wells Fargo & CompanyBoost TargetOverweight$176.00 ➝ $183.00
2/8/2021Morgan StanleyBoost TargetOverweight$170.00 ➝ $180.00
2/8/2021Raymond JamesBoost TargetStrong-Buy$170.00 ➝ $187.00
2/8/2021Wells Fargo & CompanyBoost TargetOverweight$165.00 ➝ $176.00
2/8/2021Leerink PartnersBoost TargetPositive ➝ Outperform$185.00 ➝ $190.00
2/8/2021Deutsche Bank AktiengesellschaftBoost TargetHold$146.00 ➝ $160.00
2/5/2021Needham & Company LLCBoost TargetStrong-Buy$185.00 ➝ $192.00
2/5/2021OppenheimerInitiated CoverageBuy$173.00
2/5/2021Piper SandlerBoost TargetOverweight$185.00 ➝ $195.00
1/27/2021JMP SecuritiesBoost TargetOutperform$165.00 ➝ $180.00
1/25/2021BTIG ResearchBoost TargetBuy$160.00 ➝ $173.00
1/8/2021Piper SandlerBoost TargetOverweight$160.00 ➝ $185.00
1/6/2021Truist FinancialBoost Target$152.00 ➝ $174.00
1/4/2021Evercore ISIUpgradeIn-Line ➝ Outperform$175.00
12/24/2020ArgusBoost TargetBuy$160.00 ➝ $170.00
12/24/2020Raymond JamesReiterated RatingBuy$170.00
12/18/2020Needham & Company LLCBoost TargetStrong-Buy$168.00 ➝ $185.00
12/15/2020Morgan StanleyBoost TargetOverweight$150.00 ➝ $170.00
12/15/2020The Goldman Sachs GroupUpgradeBuy ➝ Conviction-Buy
12/14/2020Leerink PartnersBoost TargetOutperform$167.00 ➝ $175.00
11/9/2020OppenheimerBoost TargetOutperform$150.00 ➝ $155.00
11/9/2020Credit Suisse GroupBoost TargetUnderperform$99.00 ➝ $106.00
11/9/2020Leerink PartnersBoost TargetOutperform$160.00 ➝ $167.00
10/27/2020CowenBoost TargetPositive ➝ Market Perform$130.00 ➝ $150.00
10/20/2020Northland SecuritiesInitiated CoverageMarket Perform$150.00
10/12/2020Raymond JamesBoost TargetStrong-Buy$150.00 ➝ $170.00
10/5/2020Leerink PartnersBoost TargetOutperform$153.00 ➝ $160.00
9/11/2020Wolfe ResearchInitiated CoverageOutperform$174.00
9/4/2020ArgusBoost Target$145.00 ➝ $160.00
8/18/2020Morgan StanleyReiterated RatingBuy$150.00
8/5/2020Credit Suisse GroupReiterated RatingSell$99.00
8/5/2020Morgan StanleyBoost TargetOverweight$140.00 ➝ $150.00
8/5/2020OppenheimerBoost TargetOutperform$138.00 ➝ $150.00
8/5/2020Leerink PartnersBoost TargetOutperform$146.00 ➝ $153.00
8/5/2020Raymond JamesBoost TargetStrong-Buy$140.00 ➝ $150.00
8/5/2020CitigroupBoost TargetBuy$140.00 ➝ $155.00
8/4/2020Needham & Company LLCInitiated CoverageStrong-Buy$148.00 ➝ $162.00
8/4/2020BTIG ResearchReiterated RatingBuy$139.00
8/4/2020OppenheimerReiterated RatingBuy$138.00
7/15/2020Leerink PartnersBoost TargetOutperform$136.00 ➝ $146.00
5/28/2020OppenheimerInitiated CoverageBuy$138.00
5/18/2020JMP SecuritiesLower TargetPositive ➝ Outperform$175.00 ➝ $150.00
5/12/2020UBS GroupLower TargetBuy$180.00 ➝ $165.00
5/12/2020Stifel NicolausBoost TargetBuy$111.00 ➝ $130.00
5/12/2020SunTrust BanksBoost TargetBuy$125.00 ➝ $132.00
5/12/2020Deutsche Bank AktiengesellschaftLower TargetHold$160.00 ➝ $146.00
5/12/2020Wells Fargo & CompanyBoost TargetOverweight$124.00 ➝ $132.00
5/12/2020Leerink PartnersBoost TargetOutperform$130.00 ➝ $136.00
5/12/2020Raymond JamesBoost TargetStrong-Buy$136.00 ➝ $140.00
5/12/2020CitigroupBoost TargetBuy$125.00 ➝ $140.00
5/11/2020OppenheimerLower TargetOutperform$141.00 ➝ $138.00
5/11/2020Wells Fargo & CompanyReiterated RatingBuy
5/11/2020Piper SandlerLower TargetIn-Line ➝ Overweight$175.00 ➝ $160.00
5/11/2020Needham & Company LLCLower TargetStrong-Buy$153.00 ➝ $148.00
4/28/2020OppenheimerLower TargetOutperform$175.00 ➝ $141.00
4/28/2020GuggenheimDowngradeBuy ➝ Neutral
4/19/2020Evercore ISIDowngradeOutperform ➝ In-Line
4/13/2020Raymond JamesLower TargetStrong-Buy$190.00 ➝ $136.00
4/7/2020Leerink PartnersBoost TargetOutperform$121.00 ➝ $130.00
4/7/2020SunTrust BanksLower TargetBuy$179.00 ➝ $125.00
4/7/2020BTIG ResearchLower TargetBuy$170.00 ➝ $130.00
4/7/2020Needham & Company LLCLower TargetStrong-Buy$189.00 ➝ $153.00
3/27/2020Morgan StanleyLower TargetOverweight$175.00 ➝ $140.00
3/27/2020CitigroupLower TargetBuy$168.00 ➝ $125.00
3/25/2020Leerink PartnersLower TargetOutperform$181.00 ➝ $121.00
3/24/2020Stifel NicolausLower TargetBuy$180.00 ➝ $93.00
3/6/2020Credit Suisse GroupLower TargetOutperform$125.00 ➝ $115.00
3/4/2020CitigroupInitiated CoverageBuy$168.00
2/12/2020The Goldman Sachs GroupInitiated CoverageBuy$177.00
2/6/2020JMP SecuritiesReiterated RatingAverage ➝ Outperform$175.00
2/5/2020OppenheimerBoost Target$165.00 ➝ $175.00
2/5/2020Robert W. BairdBoost TargetOutperform$161.00 ➝ $172.00
2/5/2020Deutsche Bank AktiengesellschaftBoost TargetHold$144.00 ➝ $160.00
2/5/2020Credit Suisse GroupBoost TargetUnderperform$120.00 ➝ $125.00
2/5/2020BTIG ResearchReiterated RatingBuy$170.00
2/5/2020Morgan StanleyBoost TargetOverweight$170.00 ➝ $175.00
2/5/2020Raymond JamesBoost TargetPositive ➝ Strong-Buy$170.00 ➝ $190.00
2/4/2020Piper SandlerBoost TargetOverweight$170.00 ➝ $175.00
2/4/2020Needham & Company LLCReiterated RatingStrong-Buy$187.00 ➝ $189.00
1/10/2020Wells Fargo & CompanyBoost TargetOverweight$165.00 ➝ $170.00
1/7/2020SunTrust BanksInitiated CoverageBuy$179.00
1/7/2020Piper SandlerUpgradeNeutral ➝ Overweight$140.00 ➝ $170.00
1/7/2020Piper Sandler CompaniesUpgradeNeutral ➝ Overweight$140.00 ➝ $170.00
1/3/2020Deutsche Bank AktiengesellschaftInitiated CoverageHold$108.00
1/2/2020CitigroupUpgradeNeutral ➝ Buy
(Data available from 12/21/2019 forward)

News Sentiment Rating

1.19 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 33 very positive mentions
  • 25 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 26 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 14 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 26 very positive mentions
  • 19 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 29 very positive mentions
  • 20 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 23 very positive mentions
  • 10 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 36 very positive mentions
  • 27 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 49 very positive mentions
  • 16 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 49 very positive mentions
  • 16 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Zimmer Biomet logo
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers robotic, surgical, and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Read More

Today's Range

Now: $107.12
Low: $105.34
High: $107.78

50 Day Range

MA: $108.09
Low: $102.35
High: $113.02

52 Week Range

Now: $107.12
Low: $101.47
High: $133.90

Volume

3,969,105 shs

Average Volume

1,504,955 shs

Market Capitalization

$21.32 billion

P/E Ratio

20.37

Dividend Yield

0.89%

Beta

1.02

Frequently Asked Questions

What sell-side analysts currently cover shares of Zimmer Biomet?

The following sell-side analysts have issued stock ratings on Zimmer Biomet in the last year: Argus, Barclays PLC, BTIG Research, Canaccord Genuity Group Inc., Citigroup Inc., Evercore ISI, JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Robert W. Baird, Royal Bank of Canada, StockNews.com, TD Cowen, The Goldman Sachs Group, Inc., TheStreet, Truist Financial Co., UBS Group AG, Wells Fargo & Company, and Wolfe Research.
View the latest analyst ratings for ZBH.

What is the current price target for Zimmer Biomet?

0 Wall Street analysts have set twelve-month price targets for Zimmer Biomet in the last year. Their average twelve-month price target is $123.33, suggesting a possible upside of 15.1%. Argus has the highest price target set, predicting ZBH will reach $150.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $107.00 for Zimmer Biomet in the next year.
View the latest price targets for ZBH.

What is the current consensus analyst rating for Zimmer Biomet?

Zimmer Biomet currently has 2 sell ratings, 11 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ZBH, but not buy more shares or sell existing shares.
View the latest ratings for ZBH.

What other companies compete with Zimmer Biomet?

Other companies that are similar to Zimmer Biomet include Solventum, Smith & Nephew, Penumbra, Glaukos and Bausch + Lomb. Learn More about companies similar to Zimmer Biomet.

How do I contact Zimmer Biomet's investor relations team?

Zimmer Biomet's physical mailing address is 345 EAST MAIN STREET, WARSAW IN, 46580. The medical equipment provider's listed phone number is (574) 267-6131 and its investor relations email address is [email protected]. The official website for Zimmer Biomet is www.zimmerbiomet.com. Learn More about contacing Zimmer Biomet investor relations.